Beam Therapeutics (MEX:BEAM) Inventories, Finished Goods: MXN0 Mil (As of Mar. 2026)


MEX:BEAM Beam Therapeutics Inc MEX:BEAM
65 GF Score
Price MXN628.46
GF Value MXN507.79
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Beam Therapeutics Inventories, Finished Goods?

Beam Therapeutics MEX:BEAM 65 Inventories, Finished Goods is MXN0 Mil as of Mar. 2026. GuruFocus rates MEX:BEAM with a GF Score™ of 65/100 and a GF Value™ of MXN507.79 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Beam Therapeutics Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Beam Therapeutics's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beam Therapeutics Inventories, Finished Goods Chart

Beam Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Beam Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:BEAM
65GF Score
Beam Therapeutics Inc MEX:BEAM
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beam Therapeutics Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of MXN0 Mil mean?
Beam Therapeutics (MEX:BEAM) has a Inventories, Finished Goods of MXN0 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Beam Therapeutics and its competitors.
Is Beam Therapeutics' Inventories, Finished Goods too high?
Beam Therapeutics' current Inventories, Finished Goods is MXN0 Mil. Overall, Beam Therapeutics has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Inventories, Finished Goods compare to ELVN and IDYA?
Beam Therapeutics' Inventories, Finished Goods of MXN0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current Inventories, Finished Goods is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN507.79, compared to a current price of MXN628.46 — trading 23.8% above its estimated fair value. The current Inventories, Finished Goods is MXN0 Mil. Beam Therapeutics' overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current Inventories, Finished Goods is MXN0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued. The current stock price of MXN628.46 is trading 23.8% above its estimated GF Value™ of MXN507.79. GuruFocus considers Beam Therapeutics to be Modestly Overvalued.

Key valuation signals for MEX:BEAM:

  • Inventories, Finished Goods: MXN0 Mil
  • GF Value™: MXN507.79 vs. price of MXN628.46 (23.8% above fair value)
  • GF Score™: 65/100 with 6 warning signs

No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beam Therapeutics Business Description

Other Exchanges BEAM:USA
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
65GF Score

Get the complete analysis for MEX:BEAM

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN628.46
Price
MXN507.79
GF Value